News & Views Published: 01 November 2004 CD28-B7 bidirectional signaling: a two-way street to activation Eric C Logue & William C Sha Nature Immunology 5, 1103–1105 (2004) Cite this article ...

T cells can be engineered to target tumor cells by transduction of tumor-specific chimeric receptors, consisting of an extracellular antigen-binding domain and an intracellular signaling domain ...

However, the CD28 CAR had significantly higher intensity and kinetics of signaling compared to 4-1BB. This increased signaling strength lead to a robust fast acting effector cell-like profile with ...

T cells can activate themselves to fight tumors Scientists find an auto-signaling mechanism driving the T cell anti-tumor response Date: May 8, 2023 Source: University of California - San Diego ...

“However, in peripheral tissues, APCs expressing B7 ligands are relatively scarce. This raises the question of whether and how CD28 co-stimulation occurs in peripheral tissues.

The CD28 signal is diminished in cancer because tumor cells do not typically express CD28 ligands (i.e., CD80 and CD86), which leads to potentially compromised activity of CD3 T cell engagers or ...

After a closer look, the researchers discovered that CD28 activates key signaling pathways involving LCK, CD3ζ and ZAP70 in the CAR NK cells to enhance their anti-tumor activity.

Dysregulated AKT phosphorylation following CD28 co-stimulation Mechanistically, the study identified that PP2A maintains CD8+ T cell effector functions through modulation of the PI3K-AKT signaling ...

She found that CD27 stimulation by 70 at high doses antagonized CD28 signaling, transiently restrained proliferation and induced a metabolic, transcriptional, and epigenetic state that resembled ...

In signal 1, T-cell receptors recognize a cancer protein. This paves the way for signal 2, in which costimulatory receptors, most powerfully CD28, cluster at the interface of T cells and target ...

Targeted signaling through the CD28 pathway is showing a lot of promise as an effective strategy for overcoming the challenges presented by solid tumors.

Rondo Therapeutics Publishes Preclinical Data on RNDO-564, a Novel CD28 x Nectin-4 Co-Stimulatory Bispecific Antibody for the Treatment of Bladder Cancer Provided by Business Wire Apr 8, 2025, 4: ...